Jewell C M, Webster J C, Burnstein K L, Sar M, Bodwell J E, Cidlowski J A
Laboratory of Integrative Biology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
J Steroid Biochem Mol Biol. 1995 Nov;55(2):135-46. doi: 10.1016/0960-0760(95)00174-x.
We have analyzed structural and functional features of the human glucocorticoid receptor (hGR) for their effects on receptor subcellular distribution. COS 1 cells transiently transfected with wild type and mutant hGR cDNAs were assessed immunocytochemically using well-characterized antipeptide antibodies to the hGR. The effect of administration of steroid hormones (and the antiglucocorticoid RU486) on receptor localization was evaluated. Unliganded wild type receptors expressed in COS 1 cells were predominately cytoplasmic. Addition of glucocorticoids or the glucocorticoid receptor antagonist, RU486, resulted in complete translocation of these receptors into the nucleus whereas non-glucocorticoid steroids or dibutyryl cAMP were not effective in promoting nuclear translocation. Thus, nuclear translocation was specific for steroids capable of high affinity binding to the hGR. To elucidate the potential role of receptor domains in receptor localization, COS 1 cells transiently transfected with various receptor cDNA mutants were analyzed in a similar manner. Translocation of an hGR deletion mutant lacking the majority of the amino terminus (deletion of amino acids 77-262) was identical to the wild type receptor despite the absence of a transactivation domain. Receptors in which the DNA binding domain was either partially or totally deleted showed an impaired capacity to undergo hormone-inducible nuclear translocation. Deletion of the hinge region of the hGR (which also contains part of the nuclear localization signal, NL1) resulted in receptor localization in the cytoplasm. Mutants in the ligand binding domain exhibited two localization phenotypes, exclusively nuclear or cytoplasmic. Receptor mutants truncated after amino acid 550 were found in the nucleus in the presence and absence of hormone consistent with the existence of nuclear localization inhibitory sequences in the ligand binding domain of the receptor. However, a linker insertion mutant (at amino acid 582) which results in a receptor deficient in ligand binding did not undergo nuclear translocation indicating that nuclear localization inhibitory sequences were intact in this mutant. The role of receptor phosphorylation on hormone induced nuclear translocation was also examined. Mouse glucocorticoid receptors which contained mutations of certain hormone inducible phosphorylation sites exhibited translocation properties similar to wild type mGR indicating that these phosphorylation sites on the receptor do not play a major role in hormone inducible nuclear translocation.
我们分析了人糖皮质激素受体(hGR)的结构和功能特征对其亚细胞分布的影响。使用针对hGR的特异性抗肽抗体,通过免疫细胞化学方法评估了瞬时转染野生型和突变型hGR cDNA的COS 1细胞。评估了类固醇激素(以及抗糖皮质激素RU486)给药对受体定位的影响。在COS 1细胞中表达的未结合配体的野生型受体主要位于细胞质中。添加糖皮质激素或糖皮质激素受体拮抗剂RU486会导致这些受体完全转运到细胞核中,而非糖皮质激素类固醇或二丁酰环磷腺苷在促进核转运方面无效。因此,核转运对能够与hGR高亲和力结合的类固醇具有特异性。为了阐明受体结构域在受体定位中的潜在作用,以类似方式分析了瞬时转染各种受体cDNA突变体的COS 1细胞。尽管缺少反式激活结构域,但缺乏大部分氨基末端(缺失氨基酸77 - 262)的hGR缺失突变体的转运与野生型受体相同。DNA结合结构域部分或完全缺失的受体显示出激素诱导的核转运能力受损。hGR铰链区(也包含部分核定位信号NL1)的缺失导致受体定位于细胞质中。配体结合结构域中的突变体表现出两种定位表型,即仅位于细胞核或细胞质中。在氨基酸550之后截断的受体突变体在有或没有激素的情况下都位于细胞核中,这与受体配体结合结构域中存在核定位抑制序列一致。然而,导致受体缺乏配体结合能力的接头插入突变体(在氨基酸582处)未发生核转运,表明该突变体中的核定位抑制序列完整。还研究了受体磷酸化对激素诱导的核转运的作用。含有某些激素诱导磷酸化位点突变的小鼠糖皮质激素受体表现出与野生型mGR相似的转运特性,表明受体上的这些磷酸化位点在激素诱导的核转运中不起主要作用。